{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:05:19Z","timestamp":1780031119638,"version":"3.53.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This article reports the diagnosis and treatment of an 81-year-old man with advanced prostate cancer presenting with multiple organ metastases. The patient had undergone laparoscopic radical prostatectomy 5\u202fyears prior and received intermittent postoperative endocrine therapy with leuprorelin acetate and bicalutamide. He presented with hematuria, and laboratory evaluation revealed a markedly elevated prostate-specific antigen level (total PSA 274.71\u202fng\/mL, free PSA 63.50\u202fng\/mL). Contrast-enhanced CT demonstrated bilateral renal masses, retroperitoneal lymphadenopathy, and liver metastases. A biopsy of the right renal lesion confirmed metastatic prostate acinar adenocarcinoma, with immunohistochemistry showing PSA (+), Ki67 (40%, indicating high proliferative activity), and succinate dehydrogenase subunit B (SDHB) (+). Following a change in the endocrine therapy regimen to rezvilutamide combined with degarelix, the patient\u2019s hematuria significantly improved. This case highlights the critical importance of rigorous postoperative surveillance and timely, standardized endocrine therapy in prostate cancer management. It also contributes to the limited literature on visceral metastases in castration-sensitive prostate cancer (HSPC) and underscores the need for further exploration of optimal treatment strategies for advanced metastatic disease.<\/jats:p>","DOI":"10.3389\/fmed.2026.1718567","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:52:58Z","timestamp":1780030378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiu Ming","family":"He","sequence":"first","affiliation":[{"name":"Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Hao","sequence":"additional","affiliation":[{"name":"Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Huang","sequence":"additional","affiliation":[{"name":"Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Biao","family":"Huang","sequence":"additional","affiliation":[{"name":"Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Hua","family":"Tu","sequence":"additional","affiliation":[{"name":"Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2021.09.037","article-title":"Prostate cancer dormancy and recurrence","volume":"524","author":"Cackowski","year":"2022","journal-title":"Cancer Lett"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13045-020-00978-z","article-title":"Novel therapies are changing treatment paradigms in metastatic prostate cancer","volume":"13","author":"Powers","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.eururo.2015.04.036","article-title":"Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives","volume":"69","author":"Bayne","year":"2016","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00345-022-04162-5","article-title":"Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives","volume":"41","author":"Tsaur","year":"2023","journal-title":"World J Urol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-020-03296-8","article-title":"Metastatic hormone sensitive prostate cancer: local treatment strategies","volume":"39","author":"Walz","year":"2021","journal-title":"World J Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.21873\/cgp.20463","article-title":"The clinical and genetic landscape of hereditary cancer: experience from a single clinical diagnostic laboratory","volume":"21","author":"Tsoulos","year":"2024","journal-title":"Cancer Genomics Proteomics"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/pros.24792","article-title":"Diagnostic potential of SDHB mRNA contained in serum extracellular vesicles among patients with prostate cancer","volume":"84","author":"Kato","year":"2024","journal-title":"Prostate"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.3390\/ijms23063203","article-title":"Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids","volume":"23","author":"Lee","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14737159.2020.1785288","article-title":"An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer","volume":"20","author":"Br\u00f6nimann","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume":"23","author":"Gu","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1080\/14796694.2024.2418801","article-title":"The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer","volume":"20","author":"Shore","year":"2024","journal-title":"Future Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14656566.2022.2033210","article-title":"Advances with androgen deprivation therapy for prostate cancer","volume":"23","author":"Yu","year":"2022","journal-title":"Expert Opin Pharmacother"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1718567\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:53:02Z","timestamp":1780030382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1718567\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":15,"alternative-id":["10.3389\/fmed.2026.1718567"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1718567","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1718567"}}